Last updated: August 14, 2026
Cefotaxime sodium is a mature, off-patent injectable third-generation cephalosporin. Its commercial value is concentrated in hospital procurement, public-health tenders, and markets where ceftriaxone or newer beta-lactams are unavailable, contraindicated, or priced higher. The product has no meaningful originator exclusivity remaining in the United States, and standalone manufacturer revenue is generally not disclosed. Its financial profile is defined by low unit prices, fragmented generic supply, periodic shortages, and gradual substitution by longer-acting or broader-spectrum antibiotics.
What is cefotaxime sodium and how is it used?
Cefotaxime sodium is the sodium salt of cefotaxime, a parenteral third-generation cephalosporin. It is administered by intravenous or intramuscular injection and is used for serious bacterial infections caused by susceptible organisms.
Common clinical uses include:
- Lower respiratory tract infections
- Urinary tract infections
- Intra-abdominal infections
- Pelvic and gynecologic infections
- Skin and soft-tissue infections
- Septicemia
- Meningitis
- Perioperative infection prevention in selected settings
Cefotaxime has activity against many gram-negative and gram-positive pathogens, but it does not provide reliable coverage against organisms producing extended-spectrum beta-lactamases, AmpC beta-lactamases, or carbapenemases. It also lacks clinically useful activity against Enterococcus species and atypical respiratory pathogens.
The drug is commonly supplied as a sterile powder for reconstitution in vial strengths such as 500 mg, 1 g, and 2 g. Strength availability varies by manufacturer and jurisdiction.
When did cefotaxime sodium lose exclusivity?
Cefotaxime sodium lost meaningful commercial exclusivity decades ago. The drug was developed and commercialized in the late 1970s and entered broad clinical use in the early 1980s. Its principal compound and product protection expired long before the current generic market developed.
The United States has no active originator patent barrier comparable to the patent estates protecting newer antibiotics. Generic manufacturers can compete through abbreviated new drug applications, provided they meet FDA requirements for pharmaceutical equivalence, manufacturing quality, sterility, labeling, and bioequivalence where applicable.
Cefotaxime sodium exclusivity timeline
| Event |
Approximate period |
Commercial impact |
| Original development and European commercialization |
Late 1970s |
Originator launch |
| U.S. Claforan commercialization |
Early 1980s |
Hospital adoption |
| U.S. generic competition |
1990s and later |
Rapid price erosion |
| Originator patent protection |
Expired decades ago |
No current compound exclusivity |
| Current market |
Mature generic era |
Tender and supply-driven competition |
The exact patent portfolio differed by jurisdiction, and historical compound patents are no longer the principal commercial determinant. Current market access depends more on manufacturing capacity, sterile-fill capability, regulatory compliance, procurement contracts, and supply reliability.
What is the FDA regulatory status of cefotaxime sodium?
Cefotaxime sodium is an established FDA-approved injectable antibiotic. The reference product was marketed in the United States under the Claforan brand. Generic versions are approved under abbreviated pathways and are listed in FDA drug databases and the Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.
The product is a conventional small-molecule injectable rather than a biologic. It therefore does not face biosimilar competition. Generic entry is governed by the ANDA pathway rather than the biosimilar pathway established under the Public Health Service Act.
FDA regulatory requirements include:
- Sterile manufacturing and aseptic processing
- Control of endotoxins and particulate matter
- Assay and impurity specifications
- Stability through the labeled shelf life
- Container-closure integrity
- Powder reconstitution performance
- Compliance with current good manufacturing practice requirements
The FDA has historically identified cefotaxime products through injectable dosage-form listings rather than through a protected brand franchise. Market participants should distinguish active approved ANDAs from discontinued products because injectable antibiotic listings can change as manufacturers exit or re-enter the market.
What is the Orange Book status of cefotaxime sodium?
Cefotaxime sodium is an off-patent generic product with no commercially relevant Orange Book patent exclusivity expected to block ANDA competition. Any historical patents associated with the original product have expired.
The practical Orange Book position is:
| Issue |
Cefotaxime sodium status |
| Reference listed drug |
Claforan and associated reference listings |
| Dosage form |
Injectable powder for solution |
| Compound patent barrier |
Expired |
| Current originator exclusivity |
None of commercial significance |
| Generic pathway |
ANDA |
| Paragraph IV exposure |
Low for the core product |
| Formulation patent risk |
Low for conventional vials |
| Biosimilar pathway |
Not applicable |
A Paragraph IV certification is unlikely to be the central market issue for standard cefotaxime sodium vials. Generic applicants generally face no active patent estate that would require a high-value patent challenge. Any litigation risk would more likely involve manufacturing, labeling, supply agreements, or a specific delivery system rather than the basic cefotaxime molecule.
What patents protect cefotaxime sodium today?
No current, commercially meaningful patent protection is expected to cover the basic cefotaxime sodium molecule or conventional sterile-vial presentation in the United States.
Formulation and manufacturing patents
Potentially relevant intellectual-property categories include:
- Improved stability formulations
- Ready-to-use or premixed solutions
- Novel reconstitution systems
- Dual-chamber containers
- Extended-storage presentations
- Improved lyophilization processes
- Manufacturing methods that reduce degradation or impurities
These rights would be product-specific and would not generally prevent sale of standard cefotaxime sodium powder in a conventional vial. The standard generic product has limited room for differentiation because hospitals typically purchase on price, dosage availability, regulatory status, and supply reliability.
The principal technical barrier is not patent protection. It is validated sterile manufacturing at acceptable cost. Cefotaxime sodium can be sensitive to degradation conditions, and manufacturers must control moisture, temperature, reconstitution performance, and storage conditions.
How many patents cover cefotaxime sodium?
The number of active patents covering the core cefotaxime sodium product is effectively zero in the United States. Historical patents existed around the cefotaxime compound and its development, but those rights expired long ago.
A patent count should exclude:
- Expired composition-of-matter patents.
- Abandoned applications.
- Patents covering unrelated cephalosporins.
- Broad manufacturing patents that do not read on conventional cefotaxime production.
- Patents covering a different delivery platform.
For commercial analysis, the relevant question is whether an active patent blocks a standard injectable cefotaxime ANDA. The answer is generally no.
How large is the cefotaxime sodium market?
A reliable standalone global revenue figure is not publicly disclosed by the principal generic manufacturers. Cefotaxime is usually reported within broader categories such as injectable antibiotics, cephalosporins, hospital anti-infectives, or anti-infective tenders.
Its market is economically mature and comparatively low value per treatment course. Revenue is distributed across:
- Government hospital systems
- Public-health tenders
- Private hospitals
- Distributors
- Institutional pharmacies
- International procurement agencies
- Pharmaceutical wholesalers
Demand is higher in countries where cefotaxime remains included in hospital formularies and lower in markets that favor ceftriaxone, cefepime, piperacillin-tazobactam, or carbapenems.
Core market characteristics
| Market factor |
Effect on cefotaxime sodium |
| Patent status |
Enables broad generic competition |
| Unit economics |
Low to moderate, depending on country and tender |
| Demand source |
Hospitals and institutional procurement |
| Prescribing trend |
Stable to declining in high-income markets |
| Supply risk |
Meaningful because sterile injectables have limited redundancy |
| Pricing power |
Weak |
| Brand loyalty |
Limited |
| Differentiation |
Primarily availability, quality, and delivery format |
| Growth driver |
Emerging-market hospital demand and procurement cycles |
| Major risk |
Substitution by ceftriaxone and stewardship restrictions |
What is the financial trajectory for cefotaxime sodium?
Cefotaxime sodium followed the standard lifecycle of a mature injectable antibiotic:
- Originator growth: Revenue increased after launch as hospitals adopted third-generation cephalosporins for serious infections.
- Generic entry: Multiple suppliers entered after exclusivity expired.
- Price erosion: Hospital buyers shifted toward tenders and generic substitution.
- Portfolio consolidation: Manufacturers with higher costs or weaker supply positions exited.
- Mature-market stabilization: Remaining sales became dependent on institutional contracts and shortage conditions.
- Long-term pressure: Use declined in some markets as ceftriaxone and broader-spectrum agents gained share.
Cefotaxime is unlikely to generate material growth through price expansion. Revenue can rise temporarily when competitors experience manufacturing interruptions, regulatory actions, or shortages. Those gains are usually episodic and can reverse when supply normalizes.
Financial trajectory by market
United States
The U.S. market is mature and generic. Pricing is affected by group purchasing organizations, hospital systems, wholesaler contracts, and the number of active suppliers. The product may retain commercial relevance when hospitals require an alternative to ceftriaxone or when shortages affect competing injectable antibiotics.
U.S. sales are unlikely to be a major revenue contributor for any diversified manufacturer unless the company holds a strong hospital-contract position or benefits from constrained supply.
Europe
European revenue is shaped by national reimbursement systems and centralized procurement. Cefotaxime remains clinically established, but ceftriaxone and other cephalosporins compete strongly. Price levels differ substantially across countries, and tender losses can cause rapid volume changes.
Emerging markets
Emerging markets offer the strongest volume opportunity. Cefotaxime is used in hospitals where broad access to newer antibiotics is limited or where procurement systems prioritize established injectable antibiotics. Growth is constrained by low prices, local competition, currency volatility, and government purchasing power.
Which companies compete with cefotaxime sodium?
Competition operates at both the manufacturer and therapeutic levels.
Manufacturer competition
Generic cefotaxime products have been marketed by multiple regional and multinational suppliers, including companies with hospital-injectable portfolios. Product availability varies by country and regulatory status. The relevant competitive variables are:
- Active product registration
- Sterile manufacturing capacity
- Tender eligibility
- Batch-release reliability
- Supply continuity
- Pharmacovigilance performance
- Price and payment terms
The market is not controlled by a single global originator. Manufacturer share can change quickly when a supplier loses a contract or receives a manufacturing citation.
Therapeutic competition
| Drug |
Competitive position |
| Ceftriaxone |
Strongest direct substitute in many hospitals; once-daily dosing is a major advantage |
| Ceftazidime |
Alternative for selected gram-negative infections, including some antipseudomonal use |
| Cefepime |
Broader gram-negative coverage, including Pseudomonas |
| Cefazolin |
Preferred for many surgical-prophylaxis and susceptible gram-positive uses |
| Piperacillin-tazobactam |
Broader mixed infection coverage |
| Meropenem |
Reserved for severe resistant infections; higher cost and stewardship restrictions |
| Ampicillin-sulbactam |
Alternative for selected mixed infections |
Ceftriaxone is the most important commercial comparator because it often provides simpler dosing and strong hospital familiarity. Cefotaxime can retain a role in neonatal care, meningitis protocols, selected renal- or hepatic-management scenarios, and formularies that prefer it for specific clinical indications.
What generic entry risks exist for cefotaxime sodium?
Generic entry risk is high because the core product is off-patent and technically established. The principal risk to existing suppliers is not patent litigation but price competition and contract displacement.
Entry barriers
- FDA or other national regulatory approval
- Sterile injectable production
- Reliable active pharmaceutical ingredient supply
- Validation of aseptic processing
- Hospital qualification
- Tender registration
- Pharmacopoeial compliance
- Working capital for inventory and receivables
These barriers reduce the number of viable suppliers compared with oral tablets, but they do not create durable pricing power. Injectable antibiotics can experience a paradoxical market structure: low prices and weak margins coexist with supply shortages because manufacturers have limited incentive to maintain redundant capacity.
What patent litigation and settlement agreements affect cefotaxime sodium?
No major current U.S. patent litigation or branded-generic settlement is central to the cefotaxime sodium market. The product’s commercial history predates the modern high-value Paragraph IV litigation cycle for protected specialty medicines.
There is also no biosimilar litigation pathway because cefotaxime sodium is a small-molecule antibiotic. Any current disputes would more likely concern:
- Product liability
- Manufacturing quality
- Antitrust conduct in hospital procurement
- Contract termination
- Regulatory compliance
- Counterfeit or substandard product claims
- Distribution arrangements
What is the outlook for cefotaxime sodium revenue?
The base-case outlook is flat to modestly declining revenue in developed markets and selective volume growth in emerging markets. Nominal revenue can increase through tender wins, inflation-linked contract resets, or temporary shortages, but those factors do not indicate improved structural pricing power.
Base-case outlook
| Driver |
Expected effect |
| Aging product and generic competition |
Downward pressure |
| Continued hospital use |
Supports baseline demand |
| Ceftriaxone substitution |
Negative |
| Emerging-market procurement |
Positive for volume |
| Injectable manufacturing shortages |
Short-term positive for available suppliers |
| Antimicrobial stewardship |
Negative for broad empiric use |
| New formulation innovation |
Limited upside unless delivery costs fall |
| Patent expiry |
No further material effect because expiry is historical |
For investors and licensors, cefotaxime sodium is best viewed as a portfolio and supply-chain asset rather than a growth product. Its value depends on manufacturing efficiency, tender access, geographic reach, and the ability to maintain regulatory compliance during periods of competitor disruption.
How strong is the cefotaxime sodium patent estate?
The patent estate is weak from a current commercial-protection perspective. There is no meaningful composition-of-matter exclusivity, no active originator franchise, and limited scope for blocking standard generic vials through formulation patents.
The stronger competitive assets are operational:
- Qualified sterile facilities
- Low-cost production
- Multiple API sources
- Regulatory approvals in several countries
- Hospital-contract coverage
- Reliable inventory
- Ability to respond to shortages
This makes cefotaxime a manufacturing and procurement business rather than a conventional patent-protected pharmaceutical franchise.
Key Takeaways
- Cefotaxime sodium is a mature, off-patent injectable third-generation cephalosporin.
- U.S. compound and product exclusivity expired decades ago.
- The product is marketed through generic and institutional channels rather than a protected brand model.
- Standalone manufacturer revenue is generally not publicly reported.
- Ceftriaxone is the strongest therapeutic competitor because of once-daily dosing and broad hospital adoption.
- Pricing power is weak, but sterile manufacturing constraints can produce temporary supply-driven revenue gains.
- No biosimilar risk exists because cefotaxime sodium is a small molecule.
- Current commercial barriers are manufacturing quality, regulatory approval, tender access, and supply reliability.
- The financial outlook is stable to declining in developed markets, with selective volume opportunity in emerging markets.
- Cefotaxime sodium has value as a dependable hospital injectable, not as a patent-growth asset.
FAQs
Does cefotaxime sodium have patent protection in the United States?
No commercially meaningful patent protection is expected to remain for the core cefotaxime sodium molecule or conventional injectable vial.
Is cefotaxime sodium listed in the FDA Orange Book?
FDA-approved cefotaxime sodium products and their reference-product relationships are reflected through FDA drug databases and Orange Book listings, subject to product status changes.
Can a generic company file a Paragraph IV challenge for cefotaxime sodium?
A Paragraph IV challenge is theoretically available where an applicant confronts a listed patent, but it is unlikely to be commercially important for the standard cefotaxime sodium injectable because the core patent estate has expired.
Why does cefotaxime sodium remain commercially available despite low prices?
Hospitals continue to use it for established indications, and injectable antibiotic suppliers can support demand through institutional contracts, public tenders, and regional procurement programs.
Is cefotaxime sodium more commercially attractive than ceftriaxone?
Ceftriaxone generally has stronger commercial positioning because of convenient once-daily dosing and broad use. Cefotaxime can be attractive to manufacturers with lower production costs, reliable sterile capacity, and access to markets where it remains a formulary standard.
References
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
World Health Organization. (2023). The WHO AWaRe antibiotic book: Infographics and summaries. World Health Organization.
-
World Health Organization. (2023). WHO model list of essential medicines: 23rd list. World Health Organization.
-
U.S. National Library of Medicine. (2024). Cefotaxime sodium injection: Drug information and labeling. DailyMed.
